article thumbnail

Shorla gains FDA nod for first oral liquid version of Novartis' Gleevec

Fierce Pharma

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.

FDA 84
article thumbnail

Regulatory-first for gene editing therapy

European Pharmaceutical Review

The Investigational New Drug (IND) application for Intellia Therapeutics’ in vivo CRISPR-based candidate NTLA-2001, has been cleared as a gene editing therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) in the US. This supports NTLA-2001’s potential as a single-administration therapeutic.

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

STAT

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage.

FDA 123
article thumbnail

STAT+: Medicare may test policy of paying less for accelerated approval drugs

STAT

The program is widely considered a success and has worked well for many drugs, including the leukemia drug Gleevec , which the FDA approved in 2001 after a review period of just two-and-a-half months, based on study results that correctly predicted successful clinical outcomes. Continue to STAT+ to read the full story…

FDA 98
article thumbnail

FDA grants orphan drug status for Ichnos’ multiple myeloma antibody

Pharmaceutical Technology

The US FDA has granted orphan drug designation (ODD) for Ichnos Sciences’ ISB 2001 to treat patients with multiple myeloma.

FDA 52
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

FDA 103
article thumbnail

ExeVir ready for clinic with variant-targeting llama antibody

pharmaphorum

Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharma companies are beginning to focus on the threat posed by emerging variants. billion acquisition at the end of 2018, span out of VIB in 2001 and developed drugs based on similar technology.